Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Science

Background:

• Drug-eluting stents (DES) are widely used in percutaneous coronary interventions (PCIs) to reduce in-stent restenosis, replacing bare metal stents.
• Numerous studies have evaluated various antiproliferative and anti-inflammatory substances on different stent platforms.
• Physicians require evidence-based guidance due to the increasing number of approved DES options.

Purpose of the Study:

• To provide evidence-based guidance for selecting drug-eluting stents.
• To analyze the limitations of using surrogate angiographic endpoints in randomized trials.
• To identify drug-eluting stents with proven clinical benefits.

Main Methods:

• Review of randomized trials comparing drug-eluting stents.
• Analysis of primary endpoints used in drug-eluting stent studies (angiographic vs. clinical).
• Evaluation of studies with primary clinical endpoints (e.g., TVF, TVR, MACE).

Main Results:

• Differences in primary endpoints and sample sizes complicate comparisons between DES studies.
• Angiographic surrogate endpoints do not always correlate with improved clinical outcomes.
• Only three trials (SIRIUS, TAXUS-IV, TAXUS-VI) demonstrated significant clinical benefits with DES.

Conclusions:

• Drug-eluting stents have shown encouraging angiographic results, but clinical impact needs further validation.
• Adequately powered randomized trials with primary clinical endpoints are crucial for assessing DES efficacy.
• Evidence-based guidance is essential for physicians navigating the complex landscape of drug-eluting stents.